BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial

{
  "signal_id": "33045329-ad7a-c1b5-b1ac-6f7c8fc85b85",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-08-12T10:50:00+00:00",
  "company": {
    "name": "BD",
    "domain": "bd.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/bd-accelerates-advanced-tissue-regeneration-strategy-with-landmark-prevent-trial-302848604.html",
    "title": "BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial",
    "excerpt": "Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery FRANKLIN LAKES, N.J. , Aug. 12, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias. The study enrolled 477 patients across 32 sites in the United States and Europe, making it the first large, randomized study evaluating prophylactic reinforcement for incisional hernia prevention using a resorbable mesh, a common complication following abdominal surgery for which no products are currently approved. \"PREVENT reflects our commitment to extending the impact of advanced tissue regeneration into new areas of patient care,\" said Rian Seger, worldwide president of Surgery at BD. \"By evaluating Phasix™ Mesh in hernia prevention, we are building on decades of innovation in abdominal wall surgery and generating evidence that could help broaden the role of regenerative technologies for patients at risk of post-surgical complications. We are grateful to the investigators, clinical sites and patients whose...",
    "product": "Phasix Mesh",
    "summary": "BD has completed enrollment for its PREVENT clinical trial, a large-scale randomized study evaluating its Phasix™ Mesh for the prevention of incisional hernias following abdominal surgery.",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS1965600/Phasix_Flat_Mesh.jpg?id=OA2833801&p=facebook",
    "confidence": 0.9,
    "product_data": {
      "name": "Phasix Mesh",
      "full_text": "Phasix™ Mesh",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-08-12T10:50:00Z",
    "vulnerability": "prevention of incisional hernias",
    "effective_date": "2026-08-12",
    "article_sentence": "BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias."
  }
}

curl https://signals.autobound.ai/v1/signals/33045329-ad7a-c1b5-b1ac-6f7c8fc85b85 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"bd.com","limit":20}'